Virtus Fund Advisers’s PDL BioPharma, Inc. PDLI Stock Holding History

Virtus Fund Advisers’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13,704	Closed	-$133K	–	2754
2014 Q2	$133K	Buy	+13,704	New	+$122K	﹤0.01%	1206

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtus Fund Advisers's PDLI Position: Q3 2014 in Review

Virtus Fund Advisers sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 13,704 shares — an estimated $133K sold.

Virtus Fund Advisers first reported a position in PDLI in Q2 2014 and held it in 1 quarter. The position peaked at $133K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

Virtus Fund Advisers reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
Virtus Fund Advisers sold 13,704 PDL BioPharma, Inc. shares in Q3 2014, an estimated $133K.
Virtus Fund Advisers first reported a position in PDL BioPharma, Inc. in Q2 2014 and held it in 1 quarter.
Virtus Fund Advisers's PDL BioPharma, Inc. position peaked at $133K in Q2 2014.
231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.